ArticleCommunications medicine2026
Longitudinal associations of cardiovascular-kidney-metabolic syndrome with midlife or late-life mental disorders and dementia, and the mediating role of metabolomic signature.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular-Kidney-Metabolic (CKM) syndrome assesses the interconnections among metabolic, kidney, and cardiovascular diseases, rendering significant prognostic value for age-related chronic diseases and mortality. We aimed to investigate the effects of CKM syndrome on transitions between healthy status, mental disorders, and dementia and evaluate the potential mediating role of a CKM-related metabolomic signature in these associations.
methodsThis prospective longitudinal study used UK Biobank data from 375,203 midlife and older adults at baseline and 188,018 with metabolomic information. CKM was staged from 0 to 4. Mental disorders and dementia were identified via ICD-10. Multi-state models analyzed the impact of CKM on transitions from healthy status to mental disorders and dementia. Competing risk (death) models assessed the associations of CKM with specific mental disorders and dementia. Mediation role of CKM-related metabolomic signature was evaluated.
resultsWe show that per-stage CKM increase elevates hazards of transitioning from healthy to mental disorders (HR = 1.24[1.22-1.26]) and subsequently to dementia (HR = 1.38[1.21-1.58]), or directly to dementia (HR = 1.27[1.21-1.33]). Worsening CKM stages are associated with bipolar, depressive, and anxiety disorders; whilst only advanced stages (3/4) associated with all dementia types. The CKM metabolomic signature mediates 34.9% and 8.1% of associations of CKM with pre-dementia mental disorders and dementia, respectively.
conclusionsCKM syndrome is associated with pre-dementia mental disorders and dementia, emphasizing the need for regular monitoring and early intervention to manage CKM progression and reduce geriatric neuropsychiatric disturbances.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.